NO20005768L - Stabiliserte farmasöytiske preparater av <gamma>- aminosmörsyrederivater og fremgangsmåte for fremstilling av disse - Google Patents

Stabiliserte farmasöytiske preparater av <gamma>- aminosmörsyrederivater og fremgangsmåte for fremstilling av disse

Info

Publication number
NO20005768L
NO20005768L NO20005768A NO20005768A NO20005768L NO 20005768 L NO20005768 L NO 20005768L NO 20005768 A NO20005768 A NO 20005768A NO 20005768 A NO20005768 A NO 20005768A NO 20005768 L NO20005768 L NO 20005768L
Authority
NO
Norway
Prior art keywords
gamma
preparation
acid derivatives
butyric acid
pharmaceutical preparations
Prior art date
Application number
NO20005768A
Other languages
English (en)
Other versions
NO328959B1 (no
NO20005768D0 (no
Inventor
Akira Aomatsu
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15097118&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20005768(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO20005768L publication Critical patent/NO20005768L/no
Publication of NO20005768D0 publication Critical patent/NO20005768D0/no
Publication of NO328959B1 publication Critical patent/NO328959B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polymerisation Methods In General (AREA)
NO20005768A 1998-05-15 2000-11-14 Stabiliserte farmasoytiske preparater av gamma-aminosmorsyrederivater og fremgangsmate for fremstilling av disse NO328959B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP13311398 1998-05-15
PCT/US1999/010190 WO1999059573A1 (en) 1998-05-15 1999-05-10 Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same

Publications (3)

Publication Number Publication Date
NO20005768L true NO20005768L (no) 2000-11-14
NO20005768D0 NO20005768D0 (no) 2000-11-14
NO328959B1 NO328959B1 (no) 2010-06-28

Family

ID=15097118

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005768A NO328959B1 (no) 1998-05-15 2000-11-14 Stabiliserte farmasoytiske preparater av gamma-aminosmorsyrederivater og fremgangsmate for fremstilling av disse

Country Status (36)

Country Link
US (1) US7309719B1 (no)
EP (1) EP1077692B1 (no)
JP (1) JP4612923B2 (no)
KR (1) KR100602047B1 (no)
CN (1) CN1303991C (no)
AR (1) AR020323A1 (no)
AT (1) ATE271864T1 (no)
AU (1) AU768277B2 (no)
BR (1) BR9910508B1 (no)
CA (1) CA2327285C (no)
CO (1) CO5021224A1 (no)
CR (1) CR6026A (no)
CU (1) CU23253B7 (no)
DE (1) DE69918977T2 (no)
DK (1) DK1077692T3 (no)
EG (1) EG26803A (no)
ES (1) ES2221385T3 (no)
GT (1) GT199900069A (no)
HN (1) HN1999000072A (no)
HU (1) HU228771B1 (no)
ID (1) ID27724A (no)
IL (2) IL139298A0 (no)
IS (1) IS2233B (no)
MY (1) MY157878A (no)
NO (1) NO328959B1 (no)
NZ (1) NZ508015A (no)
PA (1) PA8472801A1 (no)
PE (1) PE20000556A1 (no)
PL (1) PL204921B1 (no)
PT (1) PT1077692E (no)
SI (1) SI1077692T1 (no)
SV (1) SV1999000064A (no)
TW (1) TWI243054B (no)
UY (1) UY25512A1 (no)
WO (1) WO1999059573A1 (no)
ZA (1) ZA200006484B (no)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100491282B1 (ko) 1996-07-24 2005-05-24 워너-램버트 캄파니 엘엘씨 통증 치료용 이소부틸가바 및 그의 유도체
EP1430893A1 (en) * 2000-06-16 2004-06-23 Teva Pharmaceutical Industries Ltd. Stable gabapentin containing more than 20 ppm of chloride ion
KR100667721B1 (ko) * 2000-06-16 2007-01-15 테바 파마슈티컬 인더스트리즈 리미티드 제어 범위 내의 ｐｈ를 갖는 안정한 가바펜틴
EP1384473A1 (en) * 2000-06-16 2004-01-28 Teva Pharmaceutical Industries Ltd. Stable gabapentin containing more than 20 ppm of chlorine ion
AU2001268426A1 (en) * 2000-06-16 2002-01-02 Teva Pharmaceutical Industries Ltd. Stable gabapentin containing more than 2o ppm of chlorine ion
US7056951B2 (en) * 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
DE60213592T2 (de) * 2001-05-25 2007-08-09 Warner-Lambert Co. Llc Flüssige pharmazeutische zusammensetzung
WO2005074895A1 (en) * 2004-02-04 2005-08-18 Alembic Limited Extended release coated microtablets of venlafaxine hydrochloride
CA2565095A1 (en) * 2004-05-17 2005-12-08 William S. Brusilow Decreasing brain neuronal glutamate levels using alpha-keto branched chain amino acids
NL2000281C2 (nl) 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
WO2007107835A2 (en) * 2006-03-17 2007-09-27 Aurobindo Pharma Limited Stable liquid formulations of antiepileptic agents
DE102007019071A1 (de) 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
FR2918567B1 (fr) * 2007-07-11 2012-08-03 Pf Medicament Composition pharmaceutique stable d'un sel hydrosoluble de vinorelbine.
JP2010043063A (ja) 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
SG10201505101VA (en) * 2009-05-19 2015-07-30 Neuroderm Ltd Compositions For Continuous Administration Of Dopa Decarboxylase Inhibitors
HU230031B1 (hu) 2010-03-01 2015-05-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
EP2389933A1 (en) 2010-05-25 2011-11-30 Sanovel Ilac Sanayi ve Ticaret A.S. Controlled-Release Pregabalin Compositions
EP2389934A1 (en) 2010-05-25 2011-11-30 Sanovel Ilac Sanayi ve Ticaret A.S. Controlled-Release Tablet Formulations of Pregabalin
TR201005241A1 (tr) 2010-05-25 2012-01-23 Sanovel �La� San. Ve T�C. A.�. Kontrollü salım sağlayan pregabalin solüsyon formülasyonu.
SI2640358T1 (en) 2010-11-15 2018-05-31 Neuroderm Ltd. Continuous administration of L-dopa, dopamine decarboxylase inhibitors, catechol-O-methyl transferase inhibitors, and compositions thereof
AU2013273138B2 (en) 2012-06-05 2017-06-15 Neuroderm Ltd Compositions comprising apomorphine and organic acids and uses thereof
CN103494796B (zh) * 2013-09-30 2016-01-20 浙江华义医药有限公司 普瑞巴林稳定的药物组合物及其制备方法
EP3099288A1 (en) 2014-01-28 2016-12-07 Sun Pharmaceutical Industries Ltd Stabilized gastroretentive tablets of pregabalin
WO2015136538A1 (en) 2014-03-13 2015-09-17 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
EP2923694B1 (en) * 2014-03-27 2018-11-14 Sanovel Ilac Sanayi ve Ticaret A.S. Oral liquid pharmaceutical solution of gabapentin
EP2929878A1 (en) * 2014-04-09 2015-10-14 Arven Ilac Sanayi ve Ticaret A.S. Extended release formulations of gabapentin
CA2953225A1 (en) 2015-05-26 2016-12-01 Isa Odidi Controlled extended release pregabalin
JP6919119B2 (ja) * 2017-01-23 2021-08-18 日新製薬株式会社 ３位が置換されたγ−アミノ酪酸誘導体を含有する圧縮固形医薬組成物。
CN113164423A (zh) 2018-10-04 2021-07-23 美德阿利克斯株式会社 用非水溶剂稳定化的制剂
US11654124B2 (en) 2019-07-29 2023-05-23 Amneal Pharmaceuticals Llc Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
US10792262B1 (en) * 2019-07-29 2020-10-06 Saol International Limited Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
AU2020370758B2 (en) * 2019-10-25 2025-08-14 Kyoto University Preventative or therapeutic agent for tauopathy
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
CN112843015A (zh) * 2021-04-08 2021-05-28 海南鑫开源医药科技有限公司 一种加巴喷丁胶囊制剂及其制备方法
WO2023055457A1 (en) 2021-09-29 2023-04-06 Amneal Pharmaceuticals Llc Baclofen-containing granule formulations and reduced patient exposure to metabolite variations
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087544A (en) 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4126684A (en) * 1976-02-11 1978-11-21 Ciba-Geigy Corporation 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse
US4255448A (en) * 1979-09-10 1981-03-10 Wisconsin Alumni Research Foundation Method for reducing epileptiform activity
GB8311804D0 (en) * 1983-04-29 1983-06-02 Merrell Toraude & Co Treatment of seizure disorders and pharmaceutical compositions
US4595697A (en) * 1984-03-28 1986-06-17 Merrell Dow Pharmaceuticals Inc. Treatment of seizure disorders and pharmaceutical compositions useful therein
CA1249968A (en) 1984-04-05 1989-02-14 Kazuo Kigasawa Ointment base
JPS63253022A (ja) 1987-04-08 1988-10-20 Nitto Electric Ind Co Ltd バクロフエン外用製剤
PH26730A (en) * 1988-12-30 1992-09-28 Ciba Geigy Ag Coated adhesive tablets
DE3928183A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
US5006560A (en) * 1989-12-20 1991-04-09 Schering Corporation Use of GABA-B selective agonists as anti-tussive agents
US5084479A (en) * 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
EP0458751A1 (en) * 1990-05-25 1991-11-27 Warner-Lambert Company Delivery system for cyclic amino acids with improved taste, texture and compressibility
US5025035A (en) 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
GB9023585D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
HUT59656A (en) * 1990-11-15 1992-06-29 Puetter Medice Chem Pharm Process for producing s/+/-phenyl-alkanoic acids and alpha-amino-acids containing complexes and pharmaceutical compositions containing them as active components
US6197819B1 (en) * 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
JPH0597703A (ja) * 1991-10-04 1993-04-20 Yamanouchi Pharmaceut Co Ltd 改変型組織プラスミノーゲン活性化因子含有組成物
JP3856816B2 (ja) * 1992-05-20 2006-12-13 ノースウェスターン ユニヴァーシティ 抗発作治療用のｇａｂａ及びｌ−グルタミン酸類縁体
US5629008A (en) * 1992-06-02 1997-05-13 C.R. Bard, Inc. Method and device for long-term delivery of drugs
US5792451A (en) * 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5248678A (en) * 1992-06-30 1993-09-28 Fractal Laboratories, Inc. Methods for increasing arousal and alertness and for the amelioration of comatose states
US5260337A (en) * 1992-07-29 1993-11-09 Merck & Co., Inc. Ibuprofen-muscle relaxant combinations
JP3467794B2 (ja) * 1993-03-09 2003-11-17 日本油脂株式会社 学習能向上剤
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
JPH0867636A (ja) * 1994-08-30 1996-03-12 Yamanouchi Pharmaceut Co Ltd 播種性血管内凝固症候群（ｄｉｃ）の予防治療薬
GB9420784D0 (en) * 1994-10-14 1994-11-30 Glaxo Group Ltd Medicaments
US5641512A (en) * 1995-03-29 1997-06-24 The Procter & Gamble Company Soft gelatin capsule compositions
US5510381A (en) 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
JPH1017476A (ja) * 1996-06-28 1998-01-20 Nippon Seiyaku Kk 敗血症用非経口製剤及びそれによる予防及び治療方法
WO1998003189A1 (en) * 1996-07-22 1998-01-29 Cognetix, Inc. Use of conantokins
KR100491282B1 (ko) * 1996-07-24 2005-05-24 워너-램버트 캄파니 엘엘씨 통증 치료용 이소부틸가바 및 그의 유도체
US5780431A (en) * 1996-09-20 1998-07-14 Neurobiological Technologies, Inc. Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form
US6028102A (en) * 1998-02-24 2000-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anticonvulsant drugs and pharmaceutical compositions thereof
IT1311984B1 (it) * 1999-03-26 2002-03-22 Bioindustria Lab Italiano Medi Procedimento per la preparzione di gabapentin.
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US7056951B2 (en) * 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
US6979462B1 (en) * 2000-10-03 2005-12-27 Mutual Pharmaceutical Co., Inc. Stabilization of solid drug formulations
WO2002100347A2 (en) * 2001-06-11 2002-12-19 Xenoport, Inc. Prodrugs of gaba analogs, compositions and uses thereof

Also Published As

Publication number Publication date
TWI243054B (en) 2005-11-11
IS2233B (is) 2007-04-15
JP4612923B2 (ja) 2011-01-12
HK1036586A1 (en) 2002-01-11
GT199900069A (es) 2000-11-04
SV1999000064A (es) 2000-03-31
BR9910508A (pt) 2001-01-02
NZ508015A (en) 2003-11-28
PA8472801A1 (es) 2001-12-14
AR020323A1 (es) 2002-05-08
DE69918977T2 (de) 2005-07-28
CN1303991C (zh) 2007-03-14
IS5666A (is) 2000-10-16
ID27724A (id) 2001-04-26
IL139298A (en) 2009-07-20
PL344218A1 (en) 2001-10-08
NO328959B1 (no) 2010-06-28
CA2327285C (en) 2005-06-14
DK1077692T3 (da) 2004-12-06
ES2221385T3 (es) 2004-12-16
CR6026A (es) 2008-08-26
CO5021224A1 (es) 2001-03-27
AU4073599A (en) 1999-12-06
KR100602047B1 (ko) 2006-07-19
CA2327285A1 (en) 1999-11-25
EP1077692A1 (en) 2001-02-28
MY157878A (en) 2016-07-29
SI1077692T1 (en) 2004-10-31
HUP0102022A2 (hu) 2001-11-28
US7309719B1 (en) 2007-12-18
EG26803A (en) 2014-09-21
WO1999059573A1 (en) 1999-11-25
PT1077692E (pt) 2004-12-31
JP2000034226A (ja) 2000-02-02
PE20000556A1 (es) 2000-08-10
CN1301155A (zh) 2001-06-27
IL139298A0 (en) 2001-11-25
KR20010043611A (ko) 2001-05-25
CU23253B7 (es) 2007-12-17
BR9910508B1 (pt) 2012-01-24
HN1999000072A (es) 2000-06-05
DE69918977D1 (de) 2004-09-02
UY25512A1 (es) 1999-07-19
ATE271864T1 (de) 2004-08-15
HUP0102022A3 (en) 2002-11-28
EP1077692B1 (en) 2004-07-28
HU228771B1 (en) 2013-05-28
NO20005768D0 (no) 2000-11-14
PL204921B1 (pl) 2010-02-26
WO1999059573A9 (en) 2000-05-04
ZA200006484B (en) 2002-02-11
AU768277B2 (en) 2003-12-04

Similar Documents

Publication Publication Date Title
NO20005768D0 (no) Stabiliserte farmasöytiske preparater av &lt;gamma&gt;- aminosmörsyrederivater og fremgangsmåte for fremstilling av disse
NO20005765L (no) Faste preparater inneholdende &lt;gamma&gt;-aminosmörsyrederivater og fremgangsmåte for fremstilling av disse
NO20002835L (no) 2-aryl-oksodihydropurinderivater, fremgangsmÕte for fremstilling av disse medisinske preparater inneholdende disse, og mellomprodukter derfor
NO965298D0 (no) Ny krystallmodifikasjon av CDCH, fremgangsmåte for fremstilling derav og farmasöytiske preparater inneholdende denne
NO20000227L (no) Krystallmodifikasjon av et N-fenyl-2-pyrimidinaminderivat, fremgangsmåte for dens fremstilling og dens anvendelse
NO973479L (no) Substituerte heterosykliske forbindelser, fremgangsmåte for fremstilling og farmasöytiske blandinger inneholdende samme
NO975987D0 (no) 4-Fenylaminotiazol-derivater, fremgangsmåte for fremstilling av disse og farmasöytiske blandinger inneholdende nevnte derivater
HUP0105160A3 (en) Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-betha-cyclodextrin or 2-hydroxypropyl-betha-cyclodextrin and method for its preparation and pharmaceutical compositions containing them
NO20015888D0 (no) Implanterbare gelpreparater og fremgangsmåte for fremstilling
FI945619L (fi) Syklosporiinia sisältävät nestemäiset valmisteet ja menetelmä niiden valmistamiseksi
DK0952829T3 (da) Farmaceutisk præparat af fenofibrat med høj biologisk tilgængelighed og fremgangsmåde til dets fremstilling
FI20060617L (fi) Arakidonihappo ja menetelmä sen valmistamiseksi ja sen käyttö
FI953467A7 (fi) Aminohappojohdannaisia, näitä yhdisteitä sisältävät lääkeaineet ja men etelmä niiden valmistamiseksi
NO20004741D0 (no) Farmasøytiske blandinger for forlenget peptidfrigjøring og fremstillingsmetode
FI942075L (fi) Sappihappojohdannaisten tetratsolijohdannaisia, menetelmä niiden valmistamiseksi ja näiden yhdisteiden käyttö lääkeaineina
NO20003286D0 (no) 11&lt;beta&gt;-halogen-7&lt;alfa&gt;-substituerte østratriener, fremgangsmÕte for fremstilling av farmasøytiske preparater inneholdende angitte 11&lt;beta&gt;-halogen-7&lt;alfa&gt;-substituerte østratriener, og anvendelse av disse for fremstilling av medikamenter
NO934501D0 (no) Karboksylsyrederivater, legemidler inneholdende disse forbindelser, og fremgangsmaat e for deres fremstilling
DK0773984T3 (da) Enzymholdig granuleret substans og fremgangsmåde til fremstilling heraf
ZA989064B (en) Heteroaryl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
NO20015659L (no) Purinderivater, fremstillingsmetode og farmasöytiske preparater inneholdende disse
PL307255A1 (en) Polysubstituted derivatives of 3-acylamine 5-phenyl-1,4-benzoazepin-2-one, method of obtaining them and pharmaceutical preparations containing such derivatives
NO981241D0 (no) Heteroarylsubstituerte akryloylguanidinderivater og farmasöytiske preparater inneholdende disse
PL312078A1 (en) Novel derivatives of 2-amino 4-phenylthiazole and method of obtaining them as well as pharmaceutical agents containing such derivatives
NO20021832L (no) Farmasöytiske sammensetninger av tizoksanid og nitazoksanid
NO930796D0 (no) Glykopeptidderivater, fremgangsmaate for deres fremstilling og farmasoeytiske midler inneholdende disse

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees